Status:
ACTIVE_NOT_RECRUITING
Cardiopulmonary Outcomes in Osteogenesis Imperfecta: BBD7708
Lead Sponsor:
Baylor College of Medicine
Conditions:
Osteogenesis Imperfecta
Eligibility:
All Genders
18+ years
Brief Summary
Osteogenesis imperfecta (OI) is a group of congenital and heritable bone disorders that currently affects at least 50,000 people in the United States. OI varies in severity from perinatally lethal to ...
Detailed Description
This study is cross-sectional. At the participant's one study visit, data will be obtained at a single point in time and reflect the patients' current condition. Evaluations will include family and me...
Eligibility Criteria
Inclusion
- Individuals who are able to give informed consent or have a legally authorized representative capable of giving consent on the subject's behalf
- Individuals ages 18 and older of all races and sexes
- Individuals who have been diagnosed with OI clinically and/or genetically
Exclusion
- Individuals diagnosed with respiratory illness within 6 weeks of enrollment or undergoing diagnostic studies for an active illness.
- Individuals with other skeletal dysplasia or genetic diagnosis
- Individuals diagnosed with cardiopulmonary comorbidities that affect lung compliance
Key Trial Info
Start Date :
August 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2026
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT05317637
Start Date
August 1 2022
End Date
September 1 2026
Last Update
December 3 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California Los Angeles
Los Angeles, California, United States, 90095
2
Kennedy Krieger Institute / Hugo W. Moser Research Institute
Baltimore, Maryland, United States, 21205
3
Hospital for Special Surgery
New York, New York, United States, 10021